Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus METANDREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus METANDREN.
DELATESTRYL vs METANDREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Androgen receptor agonist; binds to androgen receptors in target tissues, activating gene transcription and promoting protein synthesis, growth of male reproductive organs, and secondary sexual characteristics.
50 to 200 mg intramuscularly every 2 to 4 weeks.
Oral: 5-25 mg once daily for testosterone replacement therapy in adult males.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
The terminal elimination half-life of methyltestosterone is approximately 3-4 hours. This short half-life necessitates multiple daily dosing (e.g., 10-50 mg orally 1-3 times daily) to maintain therapeutic androgen levels. However, due to its oral administration and first-pass metabolism, the clinical effect may last longer.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Metandren (methyltestosterone) is primarily metabolized in the liver and excreted in the urine as glucuronide and sulfate conjugates. Approximately 90% of a dose is excreted renally, with less than 5% eliminated via feces. Biliary excretion is minimal.
Category C
Category C
Androgen
Androgen